Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
Karin G. Schrenk(Jena University Hospital), Andreas Hochhaus(Jena University Hospital), Gunther O. Hofmann(Jena University Hospital), Abbas Agaimy(Comprehensive Cancer Center Erlangen), Matthias Vogt(ETH Zurich), Florian Bürckenmeyer(Jena University Hospital), Wolfram Weschenfelder(Jena University Hospital), Amer Malouhi(Jena University Hospital), Martin Freesmeyer(Klinik und Poliklinik für Nuklearmedizin), Christine Kögler, René Aschenbach(Jena University Hospital), Ulf Teichgräber(Jena University Hospital), Arndt Hartmann(Friedrich-Alexander-Universität Erlangen-Nürnberg), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Nikolaus Gaßler(Ernst Abbe University of Applied Sciences Jena), Christian Spiegel(Jena University Hospital), Robert Drescher(Jena University Hospital)
Cited by 7
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
|Leukemia|2016|849
Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis #
|Hepatology|2009|762
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|660